A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2002
11/14/2002	US20020168382 Inducing immunology response
11/14/2002	US20020168380 Moderating immunology response
11/14/2002	US20020168379 Veterinary medicine; swine respiratory system disorders
11/14/2002	US20020168367 Novel immunoadhesins for treating and preventing viral and bacterial diseases
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168351 Fusion cells and cytokine compositions for treatment of disease
11/14/2002	US20020168347 Monocyte derived cells, in a purified form, presenting antigenic epitopes on their membranes after interioriztion and processing of an antigen-antibody complex, such epitope corresponding to proteolytic degradation product of antigen
11/14/2002	US20020168340 For inhibiting and treating HIV-1 and HIV-2 infections
11/14/2002	DE10122523A1 New 1,3-dihydroxybenzo-fused decalactone compounds, are cellular kinase inhibitors and hormone receptor inhibitors, useful as e.g. antitumor, anti-infective, antifungal and antiprotozoal drugs
11/14/2002	CA2827671A1 Phosphorus-containing antimicrobial compounds and methods for their use
11/14/2002	CA2483658A1 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2452245A1 Recombinant fusion proteins and the trimers thereof
11/14/2002	CA2447360A1 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	CA2447045A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002	CA2446437A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	CA2446380A1 Proteomimetic compounds and methods
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446322A1 Anti-microbial peptides and compositions
11/14/2002	CA2446204A1 Anti-virus agent
11/14/2002	CA2446120A1 Novel arylheteroalkylamine derivatives
11/14/2002	CA2446099A1 Cephem compounds
11/14/2002	CA2446062A1 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
11/14/2002	CA2445997A1 Saponin inactivated mycoplasma vaccine
11/14/2002	CA2445923A1 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	CA2445381A1 Phosphorous containing antimicrobial compounds and methods for their use
11/14/2002	CA2445271A1 Use of castanospermine esters to treat flaviviridae-related diseases
11/14/2002	CA2438978A1 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
11/14/2002	CA2435142A1 Kinases and phosphatases
11/14/2002	CA2385809A1 Alkylamide compounds
11/13/2002	EP1256588A1 Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both
11/13/2002	EP1256582A1 1h-imidazopyridine derivatives
11/13/2002	EP1256354A1 Methods for treating cancer
11/13/2002	EP1256348A1 Remedies for hepatitis c
11/13/2002	EP1256342A1 Hypoglycemics comprising organic zinc (ii) complexes
11/13/2002	EP1255849A2 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
11/13/2002	EP1255844A1 Humanized anti-ccr2 antibodies and methods of use therefor
11/13/2002	EP1255840A2 Gene cluster encoding a nystatin polyketide synthase and its manipulation and utility
11/13/2002	EP1255821A2 Protein c derivatives
11/13/2002	EP1255820A1 Glucuronoxylomannan (gxm)-o-acetylhydrolase of cryptococcus neoformans and uses thereof
11/13/2002	EP1255815A1 Porcine reproductive and respiratory syndrome virus and methods of use
11/13/2002	EP1255762A1 Phosphororganic compounds and the use thereof
11/13/2002	EP1255760A1 Clavams as protease inhibitors
11/13/2002	EP1255756A1 Saccharin derivatives as orally active elastase inhibitors
11/13/2002	EP1255753A2 Prodigiosin-derivatives as neoplastic and anti-viral agents
11/13/2002	EP1255739A1 3-aminoquinazolin-2,4-dione antibacterial agents
11/13/2002	EP1255564A2 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
11/13/2002	EP1255563A1 Composition of antigen and glycolipid adjuvant sublingual administration
11/13/2002	EP1255561A2 Proteosome influenza vaccine
11/13/2002	EP1255560A2 Cd40 ligand adjuvant for respiratory syncytial virus vaccine
11/13/2002	EP1255551A1 Use of paullone derivatives for making medicines
11/13/2002	EP1255548A1 Use of thiostrepton as an anti-mycobacterial agent
11/13/2002	EP1255543A2 Use of retinoid-type compounds as antibacterial agents
11/13/2002	EP1255541A2 Pharmaceutically active aromatic guanylhydrazones
11/13/2002	EP1255456A1 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall
11/13/2002	EP1255449A2 Nutritional formulation containing prebiotic substances
11/13/2002	EP1012139B1 Azetidinone derivatives as beta-lactamase inhibitors
11/13/2002	EP0845001B1 5'-substituted-ribofuranosyl benzimidazoles as antiviral agents
11/13/2002	EP0843557B1 Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
11/13/2002	EP0836482B1 Subunit vaccine against flavivirus infection
11/13/2002	EP0833631B1 Robustaflavone and derivatives thereof as antiviral agents
11/13/2002	EP0650489B1 Rapamycin derivatives
11/13/2002	EP0606452B1 Vector vaccines of recombinant feline herpesvirus
11/13/2002	EP0584284B9 Recombinant dna-derived cholera toxin subunit analogs
11/13/2002	EP0449958B2 Meningococcal class 1 outer-membrane protein vaccine
11/13/2002	CN1379820A Lentiviral vectors for preparation of immunotherapeutical compositions
11/13/2002	CN1379816A Human G-protein coupled receptor
11/13/2002	CN1379814A Embryonic or stem-like cell lines produced by cross species nuclear transpcantation and methods for enhancing mebryonic development by genetic alteration of donor cells or by tissue culture conditions
11/13/2002	CN1379780A Process for preparing 6-o-alkenyl-substituted erythromycin derivatives
11/13/2002	CN1379779A Process for preparation of benzoxazine derivatives and intermediates therefor
11/13/2002	CN1379772A Substituted indoles for modulating NFKB activity
11/13/2002	CN1379768A Improved aqueous solubility pharmaceutical formulations
11/13/2002	CN1379683A 疫苗 Vaccine
11/13/2002	CN1379682A Use of outer membrane protein of enterobacterium associated with RSV immunogeni peptide for preparing vaccines for intranasal administration
11/13/2002	CN1379667A Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use
11/13/2002	CN1379664A Activation and protection of cytotoxic lymphocytes using reactive oxygen metabolite inhibitor
11/13/2002	CN1379663A Vaccine composition and method of using same
11/13/2002	CN1379047A Match of organic medicine and beta-cyclodextrin derivative and its preparing process
11/13/2002	CN1379037A Ibuprofen ribavirin ester and its preparing process and application
11/13/2002	CN1378853A Charcoal powder capsule
11/13/2002	CN1378837A Application of danshinolic acid compounds in preparing medicines
11/13/2002	CN1378789A Application of medical feed for systematic treating fish disease
11/13/2002	CN1094061C Medicine for curing appendicities and its preparing method
11/12/2002	US6479673 Antiretroviral enantiomeric nucleotide analogs
11/12/2002	US6479655 TNF receptor promoter
11/12/2002	US6479633 Chemokine alpha 2
11/12/2002	US6479556 Adding polyoxyethylene sorbitan ester to an ophthalmic formulation containing a terpenoid such as camphor, borneol, and menthol to improve wettability
11/12/2002	US6479554 Immunotherapeutic agents
11/12/2002	US6479544 Therapeutic combinations of fatty acids
11/12/2002	US6479540 Compositions of tocol-soluble therapeutics
11/12/2002	US6479532 Antifungal compositions
11/12/2002	US6479530 Substituted 4(5)-(1-indanyl,-indanylmethyl, indanylmethylen), 4(5)-(1-(1,2,3,4-tetrahydronaphthyl, -naphthylmethyl and naphthylmethylen)imidazoles; hypotensive, ischemic and anxiolytic agents; nervous and muscular system disorders
11/12/2002	US6479514 Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity
11/12/2002	US6479513 Anticancer compound and enantiomer separation method useful for synthesizing said compound
11/12/2002	US6479508 Viral polymerase inhibitors
11/12/2002	US6479507 Modulation of these inflammatory cytokines is considered one of the most effective strategies to block chronic inflammation and have positive therapeutic outcomes
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479478 A 1-methylcarbapenem compound having sufficiently high degrees of both antibacterial activity and resistance to dehydropeptidase (dhp) in the living body
11/12/2002	US6479477 Substituted porphyrins
11/12/2002	US6479473 Long-acting antimicrobials

1 ... 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 ... 1798